Humana (NYSE:HUM – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 16.000- for the period, compared to the consensus EPS estimate of 16.150. The company issued revenue guidance of -.
Humana Price Performance
HUM opened at $247.10 on Friday. Humana has a 12-month low of $213.31 and a 12-month high of $475.00. The company has a market capitalization of $29.75 billion, a price-to-earnings ratio of 21.89, a PEG ratio of 2.15 and a beta of 0.53. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $273.79 and its 200-day simple moving average is $320.90.
Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities research analysts anticipate that Humana will post 16.14 earnings per share for the current fiscal year.
Humana Dividend Announcement
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday. Truist Financial lowered their target price on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research report on Friday, October 11th. Stephens restated an “equal weight” rating and set a $250.00 price objective on shares of Humana in a report on Wednesday, October 9th. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and upped their target price for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Humana has an average rating of “Hold” and an average target price of $300.50.
Get Our Latest Research Report on HUM
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- What is Put Option Volume?
- MarketBeat Week in Review – 12/16 – 12/20
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- How a New Agriculture Boom Could Propel FMC Stock Higher
- Find and Profitably Trade Stocks at 52-Week Lows
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.